Form 4: TransMedics Group CEO Waleed Hassanein Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
TransMedics Group's CEO, Waleed H. Hassanein, exercised stock options and sold shares of common stock on October 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On October 15, 2024, Waleed H. Hassanein, the President and CEO of TransMedics Group, Inc., executed a stock option to acquire 8,625 shares of common stock at a price of $13.28 per share.
- Simultaneously, Hassanein sold a total of 8,625 shares of TransMedics Group common stock on the same day.
- The sales were executed in multiple transactions at weighted average prices ranging from $131.91 to $135.04.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan established on September 6, 2023.
- Following these transactions, Hassanein directly owns 61,643 shares and indirectly owns 469,359 shares through the Waleed H. Hassanein Revocable Trust.
- He also directly owns 96,250 derivative securities in the form of stock options.
Sentiment
Score: 5
Explanation: The document reflects standard insider trading activity under a pre-arranged plan, with no clear positive or negative implications for the company's overall outlook.
Industry Context
This filing reflects routine insider trading activity under a pre-arranged plan, which is a common practice among corporate executives to diversify their holdings and manage personal finances. It doesn't necessarily indicate a change in the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 09/06/2023 | Date of entry into Rule 10b5-1 trading plan |
| 10/15/2024 | Date of stock option exercise and share sales |
| 10/17/2024 | Date of signature on the SEC Form 4 |
| 02/22/2026 | Date the option is fully vested |
| 02/22/2032 | Expiration date of the stock option |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.